Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study

被引:18
作者
Ghali, Fady
Vakar-Lopez, Funda [1 ]
Roudier, Martine P.
Garcia, Jose
Arora, Sonali [2 ]
Cheng, Heather H. [3 ,4 ]
Schweizer, Michael T. [3 ,4 ]
Haffner, Michael C. [2 ,4 ]
Lee, John K. [2 ,3 ,4 ]
Yu, Evan Y. [3 ,4 ]
Grivas, Petros [3 ,4 ]
Montgomery, Bruce [3 ,4 ]
Hsieh, Andrew C. [2 ,3 ]
Wright, Jonathan L. [5 ,7 ]
Lam, Hung-Ming [6 ,7 ]
机构
[1] Univ Washington, Sch Med, Dept Urol, Seattle, WA USA
[2] Univ Washington, Sch Med, Dept Pathol, Seattle, WA USA
[3] Fred Hutchinson Canc Ctr, Div Human Biol, Seattle, WA USA
[4] Univ Washington, Sch Med, Dept Med, Div Med Oncol, Seattle, WA USA
[5] Fred Hutchinson Canc Ctr, Clin Res Div, Seattle, WA USA
[6] Fred Hutchinson Canc Ctr, Div Publ Hlth Sci, Seattle, WA USA
[7] Univ Washington, Sch Med, Dept Urol, 1959 NE Pacific St, Seattle, WA 98195 USA
关键词
Bladder cancer; Antibody-drug conjugates; Variant histology; Metastases; ENFORTUMAB VEDOTIN; AGENT;
D O I
10.1016/j.clgc.2023.05.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We sought to characterize the expression level and subcellular localization of Nectin-4 and Trop-2, targets of novel antibody-drug conjugates in metastatic urothelial cancer, within variant bladder cancer from matched primary and metastatic sites. We find significant levels of the targets in histologic variants. Additionally, high levels of cytoplasmic rather than membrane staining is seen, which may have important clinical implications. Background: Nectin-4 and Trop-2 are transmembrane targets of FDA-approved antibody-drug conjugates (ADC) Enfortumab-vedotin (EV) and Sacituzumab govitecan (SG), respectively, for the treatment of metastatic urothelial carcinoma (mUC). The expression and role of Nectin-4 and Trop-2 in mUC variant histology is poorly described. Materials and Methods: We evaluate membranous and cytoplasmic protein expression, and mRNA levels of Nectin-4 and Trop2 within matched primary and metastatic mUC samples to determine heterogeneity of ADC targets in mUC variants. Results: Patients with mUC were consented for rapid autopsy immediately after death. Tissues from matched primary and metastatic lesions were collected. A total of 67 specimens from 20 patients were analyzed: 27 were UC, 17 plasmacytoid (PUC), 18 UC with squamous differentiation (UCSD), and 5 neuroendocrine (NE); 10 from primary and 57 from metastatic sites. All histology except NE expressed moderate-high levels of Nectin-4 and Trop-2 by both immunohistochemistry and RNAseq. Nectin-4 demonstrated prominent cytoplasmic staining in metastatic PUC and UCSD. Trop-2 demonstrated strong cytoplasmic and membrane staining in primary and metastatic tumors. Interestingly, Nectin-4 and Trop-2 expression are positively correlated at both mRNA and protein levels. Conclusion: UC and non-NE variants express notable level of Nectin-4 and Trop-2 in both primary and metastatic lesions. Membrane staining of Nectin-4 and Trop-2 is present but cytoplasmic staining is a more common event in both mUC and mUC variant histology. These findings support evaluation of EV and SG in heavily treated variant histology BC and urge attention on the clinical relevance of cytoplasmic localization of ADC targets.
引用
收藏
页码:669 / 678
页数:10
相关论文
共 23 条
[1]   Trop-2 Is a Determinant of Breast Cancer Survival [J].
Ambrogi, Federico ;
Fornili, Marco ;
Boracchi, Patrizia ;
Trerotola, Marco ;
Relli, Valeria ;
Simeone, Pasquale ;
La Sorda, Rossana ;
Lattanzio, Rossano ;
Querzoli, Patrizia ;
Pedriali, Massimo ;
Piantelli, Mauro ;
Biganzoli, Elia ;
Alberti, Saverio .
PLOS ONE, 2014, 9 (05)
[2]   HTSeq-a Python']Python framework to work with high-throughput sequencing data [J].
Anders, Simon ;
Pyl, Paul Theodor ;
Huber, Wolfgang .
BIOINFORMATICS, 2015, 31 (02) :166-169
[3]   The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer [J].
Avellini, Chiara ;
Licini, Caterina ;
Lazzarini, Raffaella ;
Gesuita, Rosaria ;
Guerra, Emanuela ;
Tossetta, Giovanni ;
Castellucci, Clara ;
Giannubilo, Stefano Raffaele ;
Procopio, Antonio ;
Alberti, Saverio ;
Mazzucchelli, Roberta ;
Olivieri, Fabiola ;
Marzioni, Daniela .
ONCOTARGET, 2017, 8 (35) :58642-58653
[4]   Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models [J].
Challita-Eid, Pia M. ;
Satpayev, Daulet ;
Yang, Peng ;
An, Zili ;
Morrison, Karen ;
Shostak, Yuriy ;
Raitano, Arthur ;
Nadell, Rossana ;
Liu, Wendy ;
Lortie, Dawn Ratay ;
Capo, Linnette ;
Verlinsky, Alla ;
Leavitt, Monica ;
Malik, Faisal ;
Avina, Hector ;
Guevara, Claudia I. ;
Dinh, Nick ;
Karki, Sher ;
Anand, Banmeet S. ;
Pereira, Daniel S. ;
Joseph, Ingrid B. J. ;
Donate, Fernando ;
Morrison, Kendall ;
Stover, David R. .
CANCER RESEARCH, 2016, 76 (10) :3003-3013
[5]   TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells [J].
Chou, Jonathan ;
Trepka, Kai ;
Sjostrom, Martin ;
Egusa, Emily A. ;
Chu, Carissa E. ;
Zhu, Jun ;
Chan, Emily ;
Gibb, Ewan A. ;
Badura, Michelle L. ;
Contreras-Sanz, Alberto ;
Stohr, Bradley A. ;
Meng, Maxwell, V ;
Pruthi, Raj S. ;
Lotan, Yair ;
Black, Peter C. ;
Porten, Sima P. ;
Koshkin, Vadim S. ;
Friedlander, Terence W. ;
Feng, Felix Y. .
EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (06) :714-718
[6]   Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer [J].
Coates, James T. ;
Sun, Sheng ;
Leshchiner, Ignaty ;
Thimmiah, Nayana ;
Martin, Elizabeth E. ;
McLoughlin, Daniel ;
Danysh, Brian P. ;
Slowik, Kara ;
Jacobs, Raquel A. ;
Rhrissorrakrai, Kahn ;
Utro, Filippo ;
Levovitz, Chaya ;
Denault, Elyssa ;
Walmsley, Charlotte S. ;
Kambadakone, Avinash ;
Stone, James R. ;
Isakoff, Steven J. ;
Parida, Laxmi ;
Juric, Dejan ;
Getz, Gad ;
Bardia, Aditya ;
Ellisen, Leif W. .
CANCER DISCOVERY, 2021, 11 (10) :2436-2445
[7]   STAR: ultrafast universal RNA-seq aligner [J].
Dobin, Alexander ;
Davis, Carrie A. ;
Schlesinger, Felix ;
Drenkow, Jorg ;
Zaleski, Chris ;
Jha, Sonali ;
Batut, Philippe ;
Chaisson, Mark ;
Gingeras, Thomas R. .
BIOINFORMATICS, 2013, 29 (01) :15-21
[8]   Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes [J].
Hoffman-Censits, Jean H. ;
Lombardo, Kara A. ;
Parimi, Vamsi ;
Kamanda, Sonia ;
Choi, Woonyoung ;
Hahn, Noah M. ;
McConkey, David J. ;
McGuire, Bridget M. ;
Bivalacqua, Trinity J. ;
Kates, Max ;
Matoso, Andres .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2021, 29 (08) :619-625
[9]   Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance [J].
Kluemper, Niklas ;
Ralser, Damian J. ;
Ellinger, Joerg ;
Roghmann, Florian ;
Albrecht, Julia ;
Below, Eduard ;
Alajati, Abdullah ;
Sikic, Danijel ;
Breyer, Johannes ;
Bolenz, Christian ;
Zengerling, Friedemann ;
Erben, Philipp ;
Schwamborn, Kristina ;
Wirtz, Ralph M. ;
Horn, Thomas ;
Nagy, Dora ;
Toma, Marieta ;
Kristiansen, Glen ;
Buettner, Thomas ;
Hahn, Oliver ;
Gruenwald, Viktor ;
Darr, Christopher ;
Erne, Eva ;
Rausch, Steffen ;
Bedke, Jens ;
Schlack, Katrin ;
Abbas, Mahmoud ;
Zschaebitz, Stefanie ;
Schwab, Constantin ;
Mustea, Alexander ;
Adam, Patrick ;
Manseck, Andreas ;
Wullich, Bernd ;
Ritter, Manuel ;
Hartmann, Arndt ;
Gschwend, Jurgen ;
Weichert, Wilko ;
Erlmeier, Franziska ;
Hoelzel, Michael ;
Eckstein, Markus .
CLINICAL CANCER RESEARCH, 2023, 29 (08) :1496-1505
[10]   Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts [J].
Lam, Hung-Ming ;
Nguyen, Holly M. ;
Labrecque, Mark P. ;
Brown, Lisha G. ;
Coleman, Ilsa M. ;
Gulati, Roman ;
Lakely, Bryce ;
Sondheim, Daniel ;
Chatterjee, Payel ;
Marck, Brett T. ;
Matsumoto, Alvin M. ;
Mostaghel, Elahe A. ;
Schweizer, Michael T. ;
Nelson, Peter S. ;
Corey, Eva .
EUROPEAN UROLOGY, 2020, 77 (02) :144-155